MedTrace Logo

PräVaNet - Structured, Intersectoral, Multiprofessional, Digitized Program to Optimize Cardiovascular Prevention

NCT05887180 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2023-06-07

No results posted yet for this study

Summary

PräVaNet is a prospective, 1:1 randomized, controlled trial to investigate the efficacy of a new, digitalized prevention strategy ("ePrevention") in cardiovascular high-risk patients with type 2 diabetes mellitus in the outpatient sector.

Conditions

  • Type 2 Diabetes
  • Arteriosclerosis
  • Arterial Hypertension
  • Lipid Metabolism Disorders

Interventions

OTHER

PräVaNet-Intervention

interdisciplinary and digitally supported prevention concept

Sponsors & Collaborators

  • Association of Statutory Health Insurance Physicians (KV Berlin)

    collaborator UNKNOWN

  • Statutory health insurance provider AOK Nordost

    collaborator UNKNOWN

  • German Foundation for the Chronically ill (DScK)

    collaborator UNKNOWN

  • aQua - Institute for Applied Quality Improvement and Research in Health Care GmbH

    collaborator UNKNOWN

  • Scientific Institute for Health Economics and Health System Research (WIG2)

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • David Sinning, MD · Deutsches Herzzentrum der Charité; Department of Cardiology, Angiology and Intensive Care Medicine

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-06-30
Completion
2025-06-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05887180 on ClinicalTrials.gov